Tobira Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
News Jul 24, 2009
Tobira Therapeutics Inc. has announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV.
These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing.
Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations.
"These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.
These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa.
Concept Life Sciences and Alderley Analytical Partner to provide Bioanalytical and DMPK ServicesNews
Companies announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.READ MORE
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.